Major drugmakers like Pfizer and Merck are proving they can still grow profits despite market noise. Pfizer beat profit expectations thanks to strong demand for its drugs and is aggressively restructuring to save another $2.5 billion, which directly boost

Verdict: Wait for MRK trigger, skip PFE entirely

This pharma momentum-reversal basket has a genuine bright spot: Merck's setup is nearly live, with price below the 20-day EMA at $128 and RSI at 36.6 already meeting two of three entry conditions, backed by a five-year backtest that returned 82.5% with a 55.0% win rate across 20 trades. But the thesis's fatal flaw is that Pfizer is nowhere near entry — its RSI sits at 65.2 against a required sub-45 threshold, and both of its exit conditions are already live, meaning the other half of this risk-parity pair is flashing a sell signal, not a buy. The idea argues these dividend-paying drugmakers offer safe, steady growth, but Pfizer's revenue contracted 1.6% year-over-year, its ROE is just 9.0% versus Merck's 34.7%, and the blended portfolio Sharpe was negative at -0.035, undercutting the quality-compounder framing. With no robust parameter setup established by the sensitivity analysis and a tight 2.4% stop that invites daily-bar whipsaws, the risk of premature exits is real. **Conviction breakdown:** Backtest evidence is solid for MRK specifically (55.0% win rate, 82.5% return) but carries coarse daily-bar fill caveats. Thesis support is moderate — Merck's fundamentals (99.6th percentile FCF) are strong, but Pfizer weakens the pair. Trade readiness is limited because PFE's conditions are deeply unmet. Risk quality is constrained by the 16.4% max drawdown and negative skew. Fundamentals are mixed: Merck is exceptional, Pfizer is a turnaround story, not a compounder.

Trade now

**MRK is nearly ready — one trigger short.** Merck closed at $128, already below its 20-day EMA of $128.76 (met) and with RSI (14) at 36.6, well under the required 45 threshold (met). The remaining gate is the stochastic oscillator crossing back above 20 from below; it currently reads 20.7, just under a point shy of that crossover. That could happen within days if the oscillator continues to tick up. The strategy's backtest on MRK produced an 82.5% return over a 60-month window across 20 trades, with a 55.0% win rate and a worst-pair drawdown of 16.4% — though exits were filled on daily bars, so reported drawdown and win rate are coarse. **PFE is nowhere near entry.** Pfizer closed at $25.41 with RSI (14) at 65.2 — the entry needs RSI below 45, so that condition is roughly 20 points away and currently in the opposite direction. Its stochastic is at 67.0, nowhere near the sub-20 zone required for a bullish crossover. Pfizer's exit conditions (RSI above 65 and price above the upper Bollinger Band) are both met, meaning the current state reflects an exit profile, not an entry setup. This is consistent with the thesis: PFE beat earnings and is restructuring for $2.5 billion in savings, but the strategy waits for pullback conditions that simply aren't present at $25.41. **What "wait" means concretely.** For MRK, monitor the daily stochastic (14). A close where the %K line crosses above 20 while price stays below $128.76 and RSI stays under 45 fires the entry. The hard stop sits at a 2.4% loss from entry (roughly $125 from current levels), and the take-profit target is 4.8% (roughly $134). That yields approximately 2:1 reward-to-risk. Note that the Fibonacci-based stop (78.6% retracement) and take-profit (127.2% extension) exits exist as layered fallbacks but are secondary to the fixed-percentage levels. No parameter-sensitivity recommendation was established — the optimization budget was exceeded — so the published parameters stand as-is.

Backtested momentum and genuine earnings power

The thesis hinges on established drugmakers demonstrating durable earnings power alongside cost discipline, and the completed five-year backtest provides concrete support for that bullish direction. The tested rule set returned 82.5% on its primary window with a 55.0% win rate across 20 trades. Over the more recent 24-month evaluation window, the signal improved to a 63.6% win rate across 11 trades, returning 20.3%. These are realized backtest results, not projections, and they directly validate the idea's argument that these dividend-paying companies can be traded profitably on momentum reversals in uptrends. The fundamental case is anchored by Merck. The company generated $12.4 billion in free cash flow on $65.0 billion in revenue, placing it in the 99.6th percentile of Health Care peers for cash generation. Return on equity stands at 34.7%, well into the 86th percentile sector-wide. The Investor's Business Daily headline notes that Merck's sales demolished Wall Street's forecasts, and the numbers corroborate the…

Scores

• Conviction score breakdown: 49
• Thesis support: 52
• Trade readiness: 40
• Risk quality: 45
• Backtest evidence: 62
• Fundamentals trend: 48

Watch items

• MRK — Stochastic (14)
• MRK — RSI (14)
• MRK — Price vs EMA (20)
• PFE — RSI (14)
• PFE — Stochastic (14)
• PFE — Price vs EMA (20)
• PFE — RSI (14)
• MRK — Price below EMA (20)
• MRK — RSI (14) below 45
• MRK — Stochastic (14) crossed above 20